Form 4: Beth Hecht Sells Xeris Biopharma Shares Under 10b5-1 Plan

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported a sale of common stock executed under a pre-arranged trading plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (XERS), sold 16,666 shares of common stock.
• The transaction occurred on July 1, 2026, with shares sold at a weighted average price of $8.03.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 8, 2025.
• Following the transaction, Hecht beneficially owns 1,161,128 shares.
• The reported sale price was a weighted average, with individual sales ranging from $7.92 to $8.19 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading.

Positives

• The sale was executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related activity.
• The reporting person retains a significant beneficial ownership of 1,161,128 shares after the sale.

Negatives

• A significant number of shares (16,666) were sold by a key executive.
• The sale occurred at a weighted average price of $8.03, which may indicate a price point management believes is favorable for selling.

Risks

• Potential for negative market perception due to a key executive selling shares, even if under a 10b5-1 plan.
• The weighted average sale price indicates a range of prices, and the specific prices at which shares were sold could be relevant to investor sentiment.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports a past transaction.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.92 to $8.19, inclusive.
• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving sales by key executives, are closely watched by investors. The use of a Rule 10b5-1 plan is a common strategy to mitigate concerns about insider trading, but significant sales can still influence market perception.

Stakeholder Impact

• Shareholders may interpret the sale by a key executive as a sign of confidence or a signal to reduce holdings, depending on other market factors.
• Employees may view executive stock sales with concern, especially if the sales are substantial.

Next Steps

• The reporting person may provide further details on individual sale prices upon request from the Issuer, security holders, or the SEC staff.

Key Dates

Keywords

Xeris Biopharma Holdings, XERS, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beth Hecht, Beneficial Ownership, Executive Compensation